Botox onabotulinumtoxinA regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Botox onabotulinumtoxinA from Allergan to treat chronic migraine. In draft guidance, the committee said Botox's benefit was "small" and the results were "confounded" by a large placebo effect. NICE also said the long-term effectiveness of the drug is uncertain. The committee asked Allergan to revise its economic model to clarify uncertainties. Comments on the draft are due March 8. ...